WO2026021373 - METHOD AND COMPOSITION FOR REGULATING GLP-1
National phase entry is expected:
Publication Number
WO/2026/021373
Publication Date
29.01.2026
International Application No.
PCT/CN2025/109535
International Filing Date
21.07.2025
Title **
[English]
METHOD AND COMPOSITION FOR REGULATING GLP-1
[French]
MÉTHODE ET COMPOSITION DE RÉGULATION DE GLP-1
Applicants **
NANJING NUTRABUILDING BIO-TECH CO., LTD.
Inventors
YI, Ronghua
JIANG, Long
WELLS, Shawn
LIAO, Kylin
Priority Data
PCT/CN2024/106700
22.07.2024
CN
PCT/CN2024/106710
22.07.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1921 | |
| EPO | Filing, Examination, Granting | 14100 | |
| Japan | Filing, Examination, Granting | 2307 | |
| South Korea | Filing, Examination, Granting | 2496 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
25,564
Contact Us
Abstract[English]
The compositions and methods for improving or regulating GLP-1 levels, stimulating GLP-1 secretion, ameliorating metabolism including losing weight, managing glucose or insulin tolerance including stimulating insulin secretion, inhibiting glucagon secretion and reducing fasting glucose levels. The compositions comprise β-aminoisobutyric acid, a physiologically acceptable salt, polymer, ester, or 3-hydroxy-3-methylbutanoic acid, a physiologically acceptable salt, polymer, ester, or tributyrin or tributyrin derivative, or mixture thereof.[French]
Compositions et méthodes d'amélioration ou de régulation des taux de GLP-1, de stimulation de la sécrétion de GLP-1, d'amélioration du métabolisme, notamment de perte de poids, de gestion de la tolérance au glucose ou à l'insuline, notamment de stimulation de la sécrétion d'insuline, d'inhibition de la sécrétion de glucagon et de réduction des taux de glucose à jeun. Les compositions comprennent de l'acide β-aminoisobutyrique, un sel, un polymère, un ester ou un acide 3-hydroxy-3-methylbutanoïque physiologiquement acceptable, un sel, un polymère, un ester ou de la tributyrine ou un dérivé de tributyrine physiologiquement acceptable, ou un mélange de ceux-ci.